New RenataDX Screening System launched for clinical laboratories

NewsGuard 100/100 Score

Waters Corporation introduced the RenataDX™ Screening System, a flow-injection tandem mass spectrometry (FIA-MS/MS) system for rapid high-throughput analysis of extracted dried blood spots and other human biological matrices.

"Waters has long been a trusted specialty measurement partner for mass spectrometry in the clinical laboratory. Continuing that history of purposeful innovation, the RenataDX Screening System is designed to ensure ease of use in clinical situations where system performance is critical to accurate analysis of biological samples," said Andy Qiu, General Manager, Global Clinical Diagnostics Business at Waters.

The need for dried blood spot analysis in clinical laboratories is growing annually. Scientists require more sample throughput capabilities to meet this demand. The bench-top system builds on the robustness and reliability that scientists have come to expect from Waters, allowing them to have the highest level of confidence in their results.

The RenataDX Screening System also offers the flexibility laboratories require to adjust to their needs. With the ability to run any suitable FIA-MS/MS laboratory developed test or ready to use reagent kit, scientists are not locked in to a prescriptive workflow. It incorporates the high-performance combination of the Xevo™ TQD IVD Mass Spectrometer, the ACQUITY™ UPLC™ I-Class IVD Binary Solvent Manager, and the 3777C IVD Sample Manager.

Driven by the combination of MassLynx (IVD) and IonLynx™ Application Manager Software, data is streamlined and seamlessly integrated into laboratory workflows, allowing scientists to get their data in real time. The IonLynx Application Manager leverages Waters' twenty years of experience processing FIA-MS/MS data, to present clinical scientists with a familiar, yet robust and reliable diagnostically-proven informatics tool.

The RenataDX Screening System is manufactured as an U.S. FDA Class I medical device and is CE Marked to the European Directive 98/79/EC (IVDD).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spicing up diabetes management: Mediterranean diet's aromatic herbs lower blood sugar